Funded Projects

Explore our currently funded projects. You may search with all three fields, then focus your results by applying any of the dropdown filters. After customizing your search, you may download results and even save your specific search for later.

Reset

Download Results

Project # Sort descending	Project Title	Research Focus Area	Research Program	Administering IC	Institution(s)	Investigator(s)	Location(s)	Year Awarded
3UG1DA049467-04S1	Great Lakes Node of the Drug Abuse Clinical Trials Network	Cross-Cutting Research	Training the Next Generation of Researchers in HEAL	NIDA	UNIVERSITY OF ILLINOIS AT CHICAGO	KARNIK, NIRANJAN	Chicago, IL	2022
NOFO Title: The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Optional) NOFO Number: RFA-DA-19-008 Summary: The Great Lakes Node of the NIDA-supported Drug Abuse Clinical Trials Network (CTN) represents all of the major academic medical centers in the Greater Chicago and Wisconsin areas and serves as a vital Midwestern hub for the CTN. This project supports a scientist from a group underrepresented in biomedicine to expand the work of this CTN node on research in several areas. These include mHealth, eHealth, artificial intelligence, natural language processing, and telehealth interventions; focus on youth/adolescent health and seniors/aging; health disparities; and professional education about opioid and substance treatment.
3UG1DA049468-03S3	Exploring Health Beliefs for Community Engagement and Diversity in Clinical Trials	Translation of Research to Practice for the Treatment of Opioid Addiction	Enhancing the National Drug Abuse Treatment Clinical Trials Network to Address Opioids	NIDA	UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR	PAGE, KIMBERLY	Albuquerque, NM	2021
NOFO Title: HEAL Initiative: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements to Support Strategies to Increase Participant Diversity, Inclusion and Engagement in Clinical Studies NOFO Number: NOT-NS-21-025 Summary: Including all population subgroups in clinical research is important to ensure that research results apply to the entire population and can be implemented effectively. However, many communities are underrepresented in health research due to individual, cultural, or structural reasons. This project aims to develop a Health Beliefs Toolkit that will be a readily accessible resource for researchers, providers, and community groups to help them engage diverse and minority populations in clinical research, particularly regarding substance use disorders. The project will examine, adapt, and test existing materials and resources targeting individual and structural barriers to research engagement. The toolkit will also assess individuals’ knowledge of health as well as health-related personal values and beliefs to enhance health and research “literacy.” The toolkit will be targeted to primary care providers, community health workers, peer counselors, agency representatives, and patient and non-patient groups to enhance practice-based research in underserved communities.
3UG1DA050072-02S2	Transitions Clinic Network: Post Incarceration Addiction Treatment, Healthcare, and Social Support (TCN PATHS) study	New Strategies to Prevent and Treat Opioid Addiction	Sleep Dysfunction as a Core Feature of Opioid Use Disorder and Recovery	NIDA	YALE UNIVERSITY	Wang, Emily Ai-hua	New Haven, CT	2020
NOFO Title: Notice of Special Interest (NOSI): NHLBI and NIDA Announce Availability of Administrative Supplements for HEAL Awardees to Address Sleep Impairments in OUD Treatment Response and Recovery Outcomes NOFO Number: NOT-HL-20-746 Summary: All forms of sleep deficiency can affect OUD treatment engagement and retention among people with OUD, particularly among people recently released from jail. Sleep deficiency may lead to a wide range of physical and psychological perturbations that may increase the likelihood of illicit opioid use, and disengagement in OUD treatment. This study will examine the association between sleep deficiency and OUD treatment retention in a sample of people receiving medications for OUD who were recently released from jail, to reduce morbidity and mortality from OUD among justice-involved individuals. The underlying rationale for this study is that sleep deficiency must be addressed in a holistic manner to support OUD treatment engagement. The specific aims are to 1) determine the prevalence of sleep deficiency and describe the sleep environment of a sample of people on MOUD recently released from jail; 2) estimate the association between sleep deficiency and OUD treatment retention; and 3) examine sleep environment as a potential mediator of sleep deficiency and OUD treatment retention in people recently released from jail. If successful, this study will provide data for the future development and testing of patient-centered interventions focusing on sleep deficiency among OUD treatment participants that enhance their retention in treatment
3UG3DA044826-02S1	COMMUNITY-BASED, CLIENT-CENTERED PREVENTION HOMES TO ADDRESS THE RURAL OPIOID EPIDEMIC	New Strategies to Prevent and Treat Opioid Addiction		NIDA	University of Wisconsin, Madison	WESTERGAARD, RYAN PATRICK; SEAL, DAVID W	MADISON, WI	2018
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) NOFO Number: PA-18-591
3UG3DA044830-02S1	DRUG INJECTION SURVEILLANCE AND CARE ENHANCEMENT FOR RURAL NORTHERN NEW ENGLAND (DISCERNNE)	New Strategies to Prevent and Treat Opioid Addiction		NIDA	Baystate Medical Center	FRIEDMANN, PETER D	SPRINGFIELD, MA	2018
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) NOFO Number: PA-18-591 Summary: This study will examine the epidemiology of injection drug use, its infectious consequences, and service accessibility among young persons who inject drugs (PWID) in 15 rural counties in Maine, New Hampshire, and Vermont, then implement an integrated telemedicine approach to treat opioid use disorder (OUD) and reduce infections and overdose. The UG3 phase will characterize the risk environment and epidemiology of OUD, its infectious complications, opioid overdose, risk behaviors, service use, and needs in young PWID in these counties. An environmental assessment of policy and infrastructure will examine available services, needs, and gaps. The UH3 phase will evaluate the effectiveness of a regionalized integrated model of expanded service delivery for rural PWID. This project will provide in-depth understanding of high-risk rural PWID, inform community response strategies, and implement a comprehensive, integrated approach to treat OUD and reduce overdose and infectious complications among PWID in the rural United States.
3UG3DA047711-02S1	PHASE 1A/1B CLINICAL TRIALS OF MULTIVALENT OPIOID VACCINE COMPONENTS	Novel Therapeutic Options for Opioid Use Disorder and Overdose	Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose	NIDA	NEW YORK STATE PSYCHIATRIC INSTITUTE	COMER, SANDRA D; PRAVETONI, MARCO	New York, NY	2019
NOFO Title: Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional) NOFO Number: RFA-DA-19-002 Summary: Opioid use disorder (OUD) is a serious public health problem that is associated with high rates of morbidity and mortality. The proposed Phase 1a/1b studies are designed to evaluate a novel treatment strategy for OUD. Specifically, the safety, immunogenicity and preliminary efficacy of a vaccine (OXY-KLH) targeted against oxycodone (Study 1) and a vaccine (M-KLH) targeted against heroin/morphine (Study 2) will be evaluated in participants diagnosed with OUD.
3UG3DA047720-01S1	Evaluation of safety and pharmacokinetics of naltrexone implant	Novel Therapeutic Options for Opioid Use Disorder and Overdose	Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose	NIDA	NEW YORK STATE PSYCHIATRIC INSTITUTE	Bisaga, Adam	New York, NY	2019
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) NOFO Number: PA-18-591 Summary: New medication treatment approaches are needed to help address the severe epidemic of opioid use disorder (OUD) and opioid overdose deaths in the U.S. Currently available medications, such as methadone, buprenorphine, and extended release injection naltrexone (XR-NTX; trade name: Vivitrol), are highly efficacious, but their effectiveness in practice is limited by poor adherence, with many patients stopping treatment prematurely and relapsing. The goal of this proposal is to develop an innovative long-acting subcutaneous implanted formulation of naltrexone, the O’Neil Long-Acting Naltrexone Implant (OLANI), toward FDA approval. Expected to produce naltrexone blood levels sufficient to block the effects of opioids for 6 months after implant, OLANI circumvents the need for adherence to monthly injections with XR-NTX and could represent an important new addition to the medical armamentarium for treatment of OUD.
3UG3DA047793-01S1	tDCS to decrease opioid relapse	Novel Therapeutic Options for Opioid Use Disorder and Overdose	Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose	NIDA	BUTLER HOSPITAL (PROVIDENCE, RI)	Abrantes, Ana M	Providence, RI	2019
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) NOFO Number: PA-18-591 Summary: Neurostimulation techniques, such as transcranial direct current stimulation (tDCS), have been used as interventions for substance use disorders. This is a supplement to the currently NIDA-funded UG3 DA047793, “tDCS to Decrease Opioid Relapse,” which will measure behavioral and brain responses following tDCS stimulation delivered during tasks that use a particular brain network involved in cognitive control, and utilizing FMRI to assess the effects. This supplement allows the researchers to add an EEG measurement to the study, to get a complete picture of how tDCS might affect the function of key brain networks in ways that could be helpful for SUDs.
3UG3DA048351-01S1	A Phase I/IIa Clinical Trial Testing the Safety and Immunogenicity of a Heroin Vaccine and its Efficacy Against Morphine Challenge.	Novel Therapeutic Options for Opioid Use Disorder and Overdose	Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose	NIDA	HENRY M. JACKSON FDN FOR THE ADV MIL/MED	MATYAS, GARY R	Bethesda, MD	2019
NOFO Title: Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional) NOFO Number: RFA-DA-19-002
3UG3DA048502-01A1S2	Non-invasive vagal nerve stimulation in opioid use disorders	Novel Therapeutic Options for Opioid Use Disorder and Overdose	Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose	NIDA	EMORY UNIVERSITY	BREMNER, JAMES DOUGLAS	Atlanta, GA	2021
NOFO Title: Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-20-222: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed) NOFO Number: NOT-NS-20-107 Summary: This research will expand the understanding of the effects of non-invasive vagal nerve stimulation on patients with opioid use disorder by examining the relationship between nerve stimulation and treatment, respiratory physiology, withdrawal symptoms, and relapse. Additionally, these relationships will be added to existing algorithms and equipment being developed by the Inan Research Lab at the Georgia Institute of Technology. Collecting and determining the quality of conventional respiration signals, as well as collecting high-resolution impedance based respiratory measurements, will help to determine the impact of non-invasive vagal nerve stimulation on breathing and lung function in people with opioid use disorder, toward development of a profile of physiological effects of non-invasive vagal nerve stimulation during opioid withdrawal.
3UG3DA050325-02S1	Use of a GLP-1 Agonist to Treat Opioid Use Disorder in Rats and Man	New Strategies to Prevent and Treat Opioid Addiction	Sleep Dysfunction as a Core Feature of Opioid Use Disorder and Recovery	NIDA	PENNSYLVANIA STATE UNIV HERSHEY MED CTR	GRIGSON, PATRICIA SUE ; BUNCE, SCOTT C	Hershey, PA	2020
NOFO Title: Notice of Special Interest (NOSI): NHLBI and NIDA Announce Availability of Administrative Supplements for HEAL Awardees to Address Sleep Impairments in OUD Treatment Response and Recovery Outcomes NOFO Number: NOT-HL-20-746 Summary: Opioid use disorder, a chronic and relapsing disease, is a significant and escalating public health concern. But, despite the availability of approved pharmacotherapies and promising therapeutic interventions, the high rates of relapse indicate a critical need for a better understanding of the factors that contribute to relapse to opioids, and for the development of new treatment approaches. Sleep problems are a common symptom in most substance use disorder syndromes, including opioid use disorder (OUD), but they are severely undertreated, partly because the standard hypnotic medications used to treat sleep disorders are themselves addictive. This study will investigate whether activating the glucagon-like peptide-1 receptor pathway can help reduce craving while improving sleep in OUD patients. The FDA-approved medication liraglutide, a GLP-1R agonist, is currently approved to treat Type II diabetes mellitus and obesity in humans. This proposal for a supplemental study will add polysomnography, the gold-standard for evaluating sleep architecture, to an ongoing study. If successful, this study will provide a strong rationale for conducting a full multi-site, Phase III clinical trial.
3UG3NS123958-01S1	Neuroimmune Mechanisms of a Humanized CCK-B Receptor scFv as Therapy for Chronic Pain Patients	Cross-Cutting Research	Training the Next Generation of Researchers in HEAL	NINDS	University of New Mexico	WESTLUND-HIGH, KARIN N	Albuquerque, NM	2022
NOFO Title: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed) NOFO Number: PA21-071 Summary: There are currently few effective therapies available for chronic nerve injury-induced pain, associated anxiety, and depression. This project aims to extend previous research aiming to uncover the mechanism of action of artificially modified immune molecules (humanized cholecystokinin-2 receptor [CCKBR] single-chain variable fragments [scFv]) on human neurons and how it reverses chronic pain and anxiety-like behaviors in mouse models. This potential treatment approach offers important advantages over existing therapies, including extreme specificity, higher affinity, brain/nerve penetrance, safety, and reduced self-immunogenicity.
3UG3TR002151-01S1	INTEGRATED MICROPHYSIOLOGICAL SYSTEM OF CEREBRAL ORGANOID AND BLOOD VESSEL FOR DISEASE MODELING AND NEUROPSYCHIATRIC DRUG SCREENING	Preclinical and Translational Research in Pain Management		NCATS	COLUMBIA UNIVERSITY HEALTH SCIENCES	LEONG, KAM W	NEW YORK, NY	2018
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) NOFO Number: PA-18-591 Summary: The clinical utility of opioids for pain treatment is limited by its risk for developing opioid usage disorders (OUD). These untoward effects impose a severe burden on society and present difficult therapeutic challenges for clinicians. We propose to extend our cerebral organoid MPS to facilitate the investigation of neuronal response to opioids and identify cellular and molecular signatures in patients vulnerable to OUD. We have assembled a team with complementary expertise in clinical characterization of OUD, cerebral organoid MPS modeling, single cell RNA-seq technology, and functional characterization of neurons in a mesolimbic reward system to test the hypothesis that midbrain MPS is a clinically relevant pre-clinical model for study of opioid usage disorder.
3UG3TR003149-02S1	Supplement to hiPSC-based DRG Tissue Mimics on Multi-well Microelectrode Arrays as a Tissue Chip Model of Acute and Chronic Nociception	Preclinical and Translational Research in Pain Management	Discovery and Validation of Novel Targets for Safe and Effective Treatment of Pain	NCATS	UNIVERSITY OF TEXAS DALLAS	BLACK, BRYAN JAMES	Dallas, TX	2020
NOFO Title: Notice of Special Interest for HEAL Initiative: Request for Administrative Supplements to Existing Grants for Identification and Validation of New Pain and Opioid Use Disorder Targets within the Understudied Druggable Genome NOFO Number: NOT-TR-20-008 Summary: This study aims to determine whether a subset of understudied genes that are expressed in human and mouse dorsal root ganglia (DRG) tissues (critical for relaying the sensation of pain from the body to the central nervous system), are also expressed in human induced pluripotent stem cell DRG mimetics. The study will also determine if these genes are involved in neuronal excitability changes under inflammatory conditions and compare these responses to those of primary DRG neurons. Third and finally, the study will optimize genetic depletion of target genes enabling future fundamental and preclinical research studies.
3UH3AR076387-02S1	Fibromyalgia TENS in Physical Therapy Study (TIPS): An Embedded Pragmatic Clinical Trial: Administrative Supplement	Cross-Cutting Research	Training the Next Generation of Researchers in HEAL	NIAMS	UNIVERSITY OF IOWA	SLUKA, KATHLEEN A; CROFFORD, LESLIE J	Iowa City, IA	2022
NOFO Title: Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for Administrative Supplements to Support Career Enhancement Related to Clinical Research on Pain (Admin Supp – Clinical Trial Not Allowed) NOFO Number: NOT-NS-22-087 Summary: This research is using a pragmatic clinical trial to test transcutaneous electrical nerve stimulation in patients with widespread muscle pain and tenderness (fibromyalgia). The research will determine if the addition of TENS to physical therapy reduces pain, increases physical therapy adherence, and helps achieve functional goals with less medication use. This project will involve early career scientists who will gain access to pragmatic research tools as well as develop the skills needed to pursue a career in clinical pain research focused on fibromyalgia.
3UH3AR076387-02S2	Fibromyalgia TENS in Physical Therapy Study (TIPS): An Embedded Pragmatic Clinical Trial	Cross-Cutting Research	Increasing Participant Diversity, Inclusion, and Engagement in HEAL Research	NIAMS	UNIVERSITY OF IOWA	SLUKA, KATHLEEN A	Iowa City, IA	2022
NOFO Title: HEAL Initiative: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements to Support Strategies to Increase Participant Diversity, Inclusion and Engagement in Clinical Studies NOFO Number: NOT-NS-22-066 Summary: Fibromyalgia is a chronic pain condition characterized by widespread musculoskeletal pain, tenderness, stiffness, fatigue, and sleep disturbance. The FAST trial (Fibromyalgia Activity Study with transcutaneous electrical nerve stimulation [TENS]) was the first study to conclusively demonstrate the clinical value of TENS for treating musculoskeletal pain. While physical therapists are trained in the use of TENS, it is underused in clinical practice. This project will test TENS in fibromyalgia patients receiving physical therapy in a real-world physical therapy practice setting. This research will determine if adding TENS to physical therapy reduces pain, increases adherence to physical therapy and allows fibromyalgia patients to reach their self-defined functional goals with less use of medication.
3UH3AR076568-02S1	Examining the effect of intersectional stigma on the treatment of negative affect in chronic low back pain	Clinical Research in Pain Management	Back Pain Consortium Research Program	NIAMS	UNIVERSITY OF PITTSBURGH AT PITTSBURGH	WASAN, AJAY D	Pittsburgh, PA	2020
NOFO Title: HEAL Initiative: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements to Support Strategies to Reduce Stigma in Pain Management and Opioid Use Disorder (OUD) and Treatment NOFO Number: NOT-OD-20-101 Summary: Patients with chronic low back pain, often have depressive and anxiety symptoms and use opioids all of which are associated with stigma. In turn stigma leads to decreased treatment seeking and adherence, increased depression and pain, and poor treatment outcomes. Intersection of these health-related stigmas may have synergistic effects. This study aims to enhance the findings of a clinical trial to test antidepressant medication and Enhanced Fear Avoidance Rehabilitation in patients with chronic low back pain and high levels of depression and anxiety. The effects of these intersecting types of stigma on the efficacy of the interventions will be evaluated to better understand the needs of the patient population and to inform development of a stigma reducing intervention that can be implemented care providers.
3UH3AR076573-03S1	Improving representation of non-Hispanic Black and Hispanic study participants in a trial of virtual reality for chronic lower back pain	Clinical Research in Pain Management	Back Pain Consortium Research Program	NIAMS	CEDARS-SINAI MEDICAL CENTER	SPIEGEL, BRENNAN	Los Angeles, CA	2021
NOFO Title: HEAL Initiative: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements to Support Strategies to Increase Participant Diversity, Inclusion and Engagement in Clinical Studies NOFO Number: NOT-NS-21-025 Summary: Digital health interventions, such as virtual reality (VR) applications, have become available for the treatment and monitoring of numerous health conditions, including pain management. A current HEAL-funded study is evaluating the role of a therapeutic VR approach for chronic low back pain. However, racial and ethnic disparities exist in patient access and response to such VR applications, as well as in the incidence and reporting of pain. For example, non-Hispanic Blacks and Hispanics are more likely to report severe pain than non-Hispanic Whites, yet are less likely to have access to digital health information and interventions. To address these disparities, this project will develop a framework to advance diversity and inclusion in digital health trials and will seek to increase the proportion of non-Hispanic Black and Hispanic participants in the ongoing VR trial by tailoring recruitment materials and using novel artificial intelligence-driven cohort building tools.
3UH3AR076573-03S2	Randomized-controlled trial of virtual reality for chronic low back pain to improve patient-reported outcomes and physical activity: Understanding Patient Predictors of Response	Clinical Research in Pain Management	Back Pain Consortium Research Program	NIAMS	CEDARS-SINAI MEDICAL CENTER	SPIEGEL, BRENNAN	Los Angeles, LA	2021
NOFO Title: Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-20-222: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed) NOFO Number: NOT-NS-20-107 Summary: Although digital health technologies are now widely available for both therapeutic and monitoring applications, there are wide variations in patient knowledge, attitudes, beliefs, and preferences regarding their uptake and effectiveness. There are also sociodemographic variations in willingness to participate in digital health research studies, both for chronic pain and other common disorders. However, few efforts have systematically examined patient-level predictors of digital health uptake and benefit among diverse individuals who experience chronic pain. This research will employ mixed methods to examine variations in engagement and benefit among diverse participants in a large clinical trial examining the benefits of virtual reality for treatment of chronic lower back pain.
3UH3AR076573-04S1	Randomized-Controlled Trial of Virtual Reality for Chronic Low-Back Pain to Improve Patient-Reported Outcomes and Physical Activity (HEAL Supplement)	Cross-Cutting Research	Training the Next Generation of Researchers in HEAL	NIAMS	CEDARS-SINAI MEDICAL CENTER	SPIEGEL, BRENNAN	Los Angeles, CA	2022
NOFO Title: Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for Administrative Supplements to Support Career Enhancement Related to Clinical Research on Pain (Admin Supp – Clinical Trial Not Allowed) NOFO Number: NOT-NS-22-087 Summary: This research is measuring patient-reported outcomes, unique physical and behavioral characteristics, and opioid use in individuals with chronic low back pain who are using virtual reality (VR) therapy. This project expands the clinical pain workforce by enhancing the ability of an early career clinician to conduct mixed-methods research involving patients using VR technology. This research will contribute new information about barriers to implementing VR technologies across diverse populations, patient preferences for using VR for relief of chronic low back pain.
3UH3AR076724-03S1	Technology Research Site for Advanced, Faster Quantitative Imaging for BACPAC	Clinical Research in Pain Management	Back Pain Consortium Research Program	NIAMS	University of California, San Francisco	MAJUMDAR, SHARMILA	San Francisco, CA	2021
NOFO Title: Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-20-222: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed) NOFO Number: NOT-NS-20-107 Summary: Chronic low back pain affects millions of Americans and is difficult to treat. Currently, there are no reliable methods to determine the best treatment options for patients, or to objectively evaluate the effectiveness of various interventions. This research will develop an imaging technology that uses machine learning to make automated assessments of spine characteristics, pain response, and patient-reported outcomes in people with chronic low back pain. This award will be used to recruit and support two postdoctoral fellows from populations underrepresented in biomedicine. The research will focus on whether use of the imaging tool helps clarify clinical diagnoses, as measured by the level of agreement between radiologists before and after using the tool.
3UH3AR076724-04S1	Technology Research Site for Advanced, Faster Quantitative Imaging for BACPAC	Cross-Cutting Research	Training the Next Generation of Researchers in HEAL	NIAMS	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	MAJUMDAR, SHARMILA	San Francisco, CA	2022
NOFO Title: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed) NOFO Number: PA-20-222 Summary: Despite the significance of spine disorders, there are few reliable methods to determine appropriate patient care and evaluate intervention effectiveness. The Back Pain Consortium Research Program (BACPAC) is developing machine learning-based methods to obtain disease-related features from biological images. This project supports a scientist from a group underrepresented in biomedicine to expand ongoing research to improve ways to interpret medical data about spine disorders and associated pain.
3UH3AR076729-02S1	The Spine Phenome Project: Enhancing Patient Diversity	Cross-Cutting Research	Increasing Participant Diversity, Inclusion, and Engagement in HEAL Research	NIAMS	OHIO STATE UNIVERSITY	MARRAS, WILLIAM STEVEN	Columbus, OH	2022
NOFO Title: HEAL Initiative: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements to Support Strategies to Increase Participant Diversity, Inclusion and Engagement in Clinical Studies NOFO Number: NOT-NS-22-066 Summary: Chronic pain is a debilitating medical condition that affects roughly 50 million people in the United States. Current diagnostics and treatments rely primarily on subjective metrics and do not target the unique biological, psychological, and social factors that contribute to an individual’s pain. This project is part of the NIH Back Pain Consortium (BACPAC) program, a patient-centered effort to address the need for effective and personalized therapies for chronic low back pain. This research will enhance patient diversity within the BACPAC research participant population.
3UH3AR077360-03S1	A sequenced-strategy for improving outcomes in patients with knee osteoarthritis pain	Clinical Research in Pain Management	Pain Management Effectiveness Research Network (ERN)	NIAMS	JOHNS HOPKINS UNIVERSITY	CAMPBELL, CLAUDIA MICHELLE (contact); CASTILLO, RENAN C; COHEN, STEVEN P	Baltimore, MD	2021
NOFO Title: Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-20-222: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed) NOFO Number: NOT-NS-20-107 Summary: Knee osteoarthritis is one of the leading causes of disability worldwide, particularly among older adults. Despite multiple guidelines for care, most patients do not receive adequate treatment, and about 30% are prescribed long-term opioids. This award will be used to recruit and support an early career faculty member from a group underrepresented in biomedicine. This research, part of the Pain Management Effectiveness Research Network will evaluate conservative and more aggressive treatments for knee osteoarthritis and determine which individual-level factors contribute to treatment outcomes.
3UH3AR077360-03S2	Increasing Participant Diversity in a 'Sequenced-Strategy to Improve Outcomes in People with Knee Osteoarthritis Pain (SKOAP)	Clinical Research in Pain Management	Pain Management Effectiveness Research Network (ERN)	NIAMS	JOHNS HOPKINS UNIVERSITY	COHEN, STEVEN P	Baltimore, MD	2021
NOFO Title: HEAL Initiative: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements to Support Strategies to Increase Participant Diversity, Inclusion and Engagement in Clinical Studies NOFO Number: NOT-NS-21-025 Summary: Knee osteoarthritis is one of the leading causes of disability worldwide, particularly among older adults. Despite multiple guidelines for care, most patients do not receive adequate treatment, and about 30% are prescribed long-term opioids. This award will be used to recruit and support an early career faculty member from a group underrepresented in biomedicine. This research, part of the Pain Management Effectiveness Research Network will evaluate conservative and more aggressive treatments for knee osteoarthritis and determine which individual-level factors contribute to treatment outcomes.